Amorphous Kinase Inhibitor Formulations And Methods Of Use Thereof
Patent No. EP4084778 (titled "Amorphous Kinase Inhibitor Formulations And Methods Of Use Thereof") was filed by Deciphera Pharmaceuticals on Dec 30, 2020. The application was issued on Nov 1, 2023.
Patent Summary
This invention provides a pharmaceutically acceptable oral composition comprising one or more excipients and a solid dispersion. The solid dispersion consists of a pharmaceutically acceptable polymer (e.g., hydroxypropylmethylcellulose acetate succinate) and an amorphous form of a compound represented by Formula (I). The amorphous form is characterized by high purity (≥95% by HPLC), high amorphous content (>95% or >96% by weight), and stability against crystallization (≤5% crystalline form) under specific humidity and temperature conditions. The composition may be formulated as tablets featuring intragranular blends (containing the solid dispersion, fillers, disintegrants, glidants, and lubricants) and extragranular blends. It is intended for treating c-KIT and PDGFRα-driven malignancies, including GIST, glioblastoma, hypereosinophilic syndrome, and various sarcomas and carcinomas.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP4084778
- Application Number
- EP20845854A
- Filing Date
- Dec 30, 2020
- Status
- Granted And Under Opposition
- Sep 29, 2023
- Publication Date
- Nov 1, 2023
- External Links
- Slate, Register , Google Patents